<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rmt</journal-id><journal-title-group><journal-title xml:lang="ru">Общая реаниматология</journal-title><trans-title-group xml:lang="en"><trans-title>General Reanimatology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1813-9779</issn><issn pub-type="epub">2411-7110</issn><publisher><publisher-name>FSBI "SRIGR" RAMS</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15360/1813-9779-2025-5-2570</article-id><article-id custom-type="elpub" pub-id-type="custom">rmt-2570</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>EXPERIMENTAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Нейропротективный эффект фармакологического прекондиционирования дихолинсукцинатом в условиях экспериментального ишемического инсульта у крыс</article-title><trans-title-group xml:lang="en"><trans-title>Neuroprotective Effect of Pharmacological Preconditioning with Dicholine Succinate in Experimental Ischemic Stroke in Rats</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8426-3371</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Помыткин</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Pomytkin</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Игорь Анатольевич Помыткин</p><p>143442, Московская обл., Красногорский р-он, п. Светлые Горы, вл. 1</p></bio><bio xml:lang="en"><p>Igor A. Pomytkin</p><p>Svetlye Gory village, bldg 1, 143442 Krasnogorsk District, Moscow Region</p></bio><email xlink:type="simple">ipomytkin@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1972-7336</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Магомедов</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Magomedov</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Марат Адессович Магомедов </p><p>119049, г. Москва, Ленинский пр-т, д. 8</p></bio><bio xml:lang="en"><p>Marat A. Magomedov</p><p>8 Leninsky Ave., 119049 Moscow</p></bio><email xlink:type="simple">MagomedovMA1@zdrav.mos.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4460-7627</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Демченко</surname><given-names>А. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Demchenko</surname><given-names>A. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Анна Григорьевна Демченко</p><p>115478, г. Москва, ул. Москва, ул. Москворечье, д. 1</p></bio><bio xml:lang="en"><p>Anna G. Demchenko</p><p>1 Moskvorechye Str., 115478 Moscow</p></bio><email xlink:type="simple">demchenkoann@yandex.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3097-344X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Балясин</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Balyazin</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Максим Витальевич Балясин</p><p>115478, г. Москва, ул. Москва, ул. Москворечье, д. 1; </p><p>117198, г. Москва, ул. Миклухо-Маклая, д. 6</p></bio><bio xml:lang="en"><p>Maxim V. Balyazin</p><p>1 Moskvorechye Str., 115478 Moscow; </p><p>6 Miklukho-Maсlaya Str., 117198 Moscow</p></bio><email xlink:type="simple">max160203@gmail.com</email><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-1621-4148</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шишкин</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shishkin</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Николай Владимирович Шишкин</p><p>107031, г. Москва, ул. Петровка, д. 25, стр. 2</p></bio><bio xml:lang="en"><p>NikolayV. Shishkin</p><p>25 Petrovka Str., Bldg. 2, 107031 Moscow</p></bio><email xlink:type="simple">Shishkin_nikolay_82@mail.ru</email><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0514-2177</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Черпаков</surname><given-names>Р. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Cherpakov</surname><given-names>R. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ростислав Александрович Черпаков</p><p>107031, г. Москва, ул. Петровка, д. 25, стр. 2</p></bio><bio xml:lang="en"><p>Rostislav A. Cherpakov</p><p>25 Petrovka Str., Bldg. 2, 107031 Moscow</p></bio><email xlink:type="simple">rcherpakov@fnkcrr.ru</email><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7145-0314</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Каркищенко</surname><given-names>В. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Karkishchenko</surname><given-names>V. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Владимир Николаевич Каркищенко</p><p>143442, Московская обл., Красногорский р-он, п. Светлые Горы, вл. 1</p></bio><bio xml:lang="en"><p>Vladimir N. Karkishchenko</p><p>Svetlye Gory village, bldg 1, 143442 Krasnogorsk District, Moscow Region</p></bio><email xlink:type="simple">vlad1672@ya.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Научный центр биомедицинских технологий Федерального медико-биологического агентства</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Scientific Center for Biomedical Technologies, Federal Medical and Biological Agency</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Городская клиническая больница № 1 им. Н. И. Пирогова Департамента здравоохранения г. Москвы</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.I. Pirogov City Clinical Hospital № 1, Moscow City Health Department</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Медико-генетический научный центр им. академика Н. П. Бочкова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Academician Bochkov Medical Genetics Research Center</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>Медико-генетический научный центр им. академика Н. П. Бочкова; &#13;
Научно-образовательный ресурсный центр клеточных технологий, Российский университет дружбы народов им. Патриса Лумумбы</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Academician Bochkov Medical Genetics Research Center; &#13;
Scientific and Educational Resource Center for Cellular Technologies, Patrice Lumumba Peoples Friendship University of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-5"><aff xml:lang="ru"><institution>Федеральный научно-клинический центр реаниматологии и реабилитологии</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>04</day><month>11</month><year>2025</year></pub-date><volume>21</volume><issue>5</issue><fpage>51</fpage><lpage>58</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Помыткин И.А., Магомедов М.А., Демченко А.Г., Балясин М.В., Шишкин Н.В., Черпаков Р.А., Каркищенко В.Н., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Помыткин И.А., Магомедов М.А., Демченко А.Г., Балясин М.В., Шишкин Н.В., Черпаков Р.А., Каркищенко В.Н.</copyright-holder><copyright-holder xml:lang="en">Pomytkin I.A., Magomedov M.A., Demchenko A.G., Balyazin M.V., Shishkin N.V., Cherpakov R.A., Karkishchenko V.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.reanimatology.com/rmt/article/view/2570">https://www.reanimatology.com/rmt/article/view/2570</self-uri><abstract><p>Инфаркт головного мозга по ишемическому типу на сегодняшний день является одной из наиболее приоритетных проблем здравоохранения. Несмотря на различие в вариантах течения ишемического и ишемически-реперфузионного повреждения нервной ткани, в конечном счете процент инвалидизации напрямую зависит от эффективности воздействия на зону пенумбра. Применение дихолинсукцината (ДХС) — нейронального инсулин-сенситайзера является перспективным фармакологическим методом лечения и профилактики последствий перенесенного инсульта.</p><sec><title>Цель исследования</title><p>Цель исследования. Изучить влияние фармакологического прекондиционирования ДХС на гибель клеток мозга в условиях экспериментального ишемического инсульта у крыс.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Ишемический инсульт у крыс (n=16) моделировали введением вазоконстриктора эндотелина-1 (ET-1) в стриатум. Эффект фармакологического прекондиционирования с использованием ДХС как активного вещества оценивали, измеряя площадь инфаркта мозга в срезах мозга, окрашенных крезиловым фиолетовым. Влияние ДХС на показатели гликолиза и окислительного фосфорилирования в первичной культуре клеток мозжечка крысы оценивали, измеряя скорость закисления внеклеточной среды и скорости поглощения кислорода, соответственно.</p></sec><sec><title>Результаты</title><p>Результаты. Курсовое введение ДХС в режиме прекондиционирования в течение 7 дней, один раз в день, в дозе 50 мг/кг per os снижает максимальную площадь зоны инфаркта мозга на 34% (p&lt;0,05) по сравнению с контролем в условиях последующего экспериментального ишемического инсульта, вызванного введением ET-1. Трехдневная инкубация первичной культуры мозжечка крыс с 50 мкМ ДХС не влияет на базовые уровни гликолиза (p=0,916) и дыхания в клетках (p=0,8346), но увеличивает гликолитический резерв клеток на 70,0% (p&lt;0,0001) по сравнению с контролем.</p></sec><sec><title>Заключение</title><p>Заключение. Впервые показан нейропротективный эффект фармакологического прекондиционирования нейрональным инсулин-сенситайзером дихолинсукцинатом в условиях ишемического инсульта. Механизм действия ДХС связан с повышением гликолитического резерва клеток мозга, то есть с увеличением способности прекондиционированных клеток вырабатывать АТФ и лактат посредством гликолиза в условиях острого падения окислительного фосфорилирования.</p></sec></abstract><trans-abstract xml:lang="en"><p>Ischemic stroke is currently considered as one of the most pressing public health issues. Despite the differences in underlying mechanisms of ischemic and ischemic-reperfusion damage to the nervous tissue, the ultimate percentage of disability depends on intervention effects on the penumbra zone. The use of dicholine succinate (DCS), a neuronal insulin-sensitizer, is a promising pharmacological agent for management and prevention of stroke consequences.</p><p>The aim of the study was to investigate the effect of pharmacological preconditioning with DCS on brain cell death in experimental ischemic stroke in rats.</p><sec><title>Materials and methods</title><p>Materials and methods. Ischemic stroke in rats (N=16) was modeled by injecting the vasoconstrictor endothelin-1 (ET-1) into the striatum. The effect of pharmacological preconditioning with DCS as the active substance was evaluated by measuring the area of brain infarction in brain sections stained with cresyl violet. The effect of DCS on glycolysis and oxidative phosphorylation in primary cultures of rat cerebellum cells was assessed by measuring the rate of extracellular acidification and the rate of oxygen uptake, respectively.</p></sec><sec><title>Results</title><p>Results. DCS administration in the preconditioning mode for 7 days, once a day orally, at a dose of 50 mg/kg, reduces the maximum area of the brain infarction zone by 34% (P&lt;0.05) compared to the control in the subsequent experimental ischemic stroke induced by ET-1 administration. Three-day incubation of rat cerebellum primary culture with 50 µM DCHS does not affect the basal levels of glycolysis (P=0.916) and cellular respiration (P=0.8346), but increases cellular glycolytic reserve by 70.0% (P&lt;0.0001) compared to the control.</p></sec><sec><title>Conclusion</title><p>Conclusion. For the first time, the neuroprotective effect of pharmacological preconditioning with the neuronal insulin-sensitizer DCS in ischemic stroke has been shown. Mechanism of DCS action associates with an increase in the glycolytic reserve of brain cells, i.e., with increased ability of preconditioned cells to produce ATP and lactate via glycolysis in case of acutely compromised oxidative phosphorylation.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>ишемический инсульт</kwd><kwd>фармакологическое прекондиционирование</kwd><kwd>дихолина сукцинат</kwd><kwd>нейропротекция</kwd><kwd>эндотелин-1</kwd><kwd>крысы</kwd><kwd>гликолиз</kwd><kwd>окислительное фосфорилирование</kwd></kwd-group><kwd-group xml:lang="en"><kwd>ischemic stroke</kwd><kwd>pharmacological preconditioning</kwd><kwd>dicholine succinate</kwd><kwd>neuroprotection</kwd><kwd>endothelin-1</kwd><kwd>rats</kwd><kwd>glycolysis</kwd><kwd>oxidative phosphorylation</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Feigin V. L., Brainin M., Norrving B., Martins S., Sacco R. L., Hacke W., Fisher M., et al. World Stroke Organization (WSO): global stroke fact sheet 2022. Int J Stroke. 2022; 17 (1): 18–29. DOI: 10.1177/17474930211065917. PMID: 34986727.</mixed-citation><mixed-citation xml:lang="en">Feigin V. L., Brainin M., Norrving B., Martins S., Sacco R. L., Hacke W., Fisher M., et al. World Stroke Organization (WSO): global stroke fact sheet 2022. Int J Stroke. 2022; 17 (1): 18–29. DOI: 10.1177/17474930211065917. PMID: 34986727.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Гусев Е. И., Скворцова В. И. Ишемия головного мозга. Москва: Медицина; 2001. 328 с.</mixed-citation><mixed-citation xml:lang="en">Gusev E. I., Skvortsova V. I. Cerebral ischemia. Moscow: Medicine; 2001. 328 p (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">O’Collins V. E., Macleod M. R., Donnan G. A., Horky L. L., van der Worp B. H., Howells D. W. 1,026 experimental treatments in acute stroke. Ann Neurol. 2006; 59 (3): 467–477. DOI: 10.1002/ana.20741. PMID: 16453316.</mixed-citation><mixed-citation xml:lang="en">O’Collins V. E., Macleod M. R., Donnan G. A., Horky L. L., van der Worp B. H., Howells D. W. 1,026 experimental treatments in acute stroke. Ann Neurol. 2006; 59 (3): 467–477. DOI: 10.1002/ana.20741. PMID: 16453316.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Lourbopoulos A., Mourouzis I., Xinaris C., Zerva N., Filippakis K., Pavlopoulos A., Pantos C. Translational block in stroke: a constructive and «out-of-the-box» reappraisal. Front Neurosci. 2021; 15: 652403. DOI: 10.3389/fnins.2021.652403. PMID: 34054413.</mixed-citation><mixed-citation xml:lang="en">Lourbopoulos A., Mourouzis I., Xinaris C., Zerva N., Filippakis K., Pavlopoulos A., Pantos C. Translational block in stroke: a constructive and «out-of-the-box» reappraisal. Front Neurosci. 2021; 15: 652403. DOI: 10.3389/fnins.2021.652403. PMID: 34054413.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Murry C. E., Jennings R. B., Reimer K. A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986; 74 (5): 1124–1136. DOI: 10.1161/01.CIR.74.5.1124. PMID: 3769170.</mixed-citation><mixed-citation xml:lang="en">Murry C. E., Jennings R. B., Reimer K. A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986; 74 (5): 1124–1136. DOI: 10.1161/01.CIR.74.5.1124. PMID: 3769170.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Liu Y., Kato H., Nakata N., Kogure K. Protection of rat hippocampus against ischemic neuronal damage by pretreatment with sublethal ischemia. Brain Res. 1992; 586 (1): 121–124. DOI: 10.1016/0006-8993(92)91380-W. PMID: 1380876.</mixed-citation><mixed-citation xml:lang="en">Liu Y., Kato H., Nakata N., Kogure K. Protection of rat hippocampus against ischemic neuronal damage by pretreatment with sublethal ischemia. Brain Res. 1992; 586 (1): 121–124. DOI: 10.1016/0006-8993(92)91380-W. PMID: 1380876.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Li S., Hafeez A., Noorulla F., Geng X.,Shao G., Ren C., Lu G., et al. Preconditioning in neuroprotection: from hypoxia to ischemia. Prog Neurobiol. 2017; 157: 79–91. DOI: 10.1016/j.pneurobio.2017.01.001. PMID: 28110083.</mixed-citation><mixed-citation xml:lang="en">Li S., Hafeez A., Noorulla F., Geng X.,Shao G., Ren C., Lu G., et al. Preconditioning in neuroprotection: from hypoxia to ischemia. Prog Neurobiol. 2017; 157: 79–91. DOI: 10.1016/j.pneurobio.2017.01.001. PMID: 28110083.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Dengler V. L., Galbraith M., Espinosa J. M. Transcriptional regulation by hypoxia inducible factors. Crit Rev Biochem Mol Biol. 2014; 49 (1): 1–15. DOI: 10.3109/10409238.2013.838205. PMID: 24099156.</mixed-citation><mixed-citation xml:lang="en">Dengler V. L., Galbraith M., Espinosa J. M. Transcriptional regulation by hypoxia inducible factors. Crit Rev Biochem Mol Biol. 2014; 49 (1): 1–15. DOI: 10.3109/10409238.2013.838205. PMID: 24099156.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Dong P., Li Q., Han H. HIF-1α in cerebral ischemia (Review). Mol Med Rep. 2022; 25 (2): 41. DOI: 10.3892/mmr.2021.12557. PMID: 34878158.</mixed-citation><mixed-citation xml:lang="en">Dong P., Li Q., Han H. HIF-1α in cerebral ischemia (Review). Mol Med Rep. 2022; 25 (2): 41. DOI: 10.3892/mmr.2021.12557. PMID: 34878158.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Zelzer E., Levy Y., Kahana C., Shilo B. Z., Rubinstein M., Cohen B. Insulin induces transcription of target genes through the hypoxiainducible factor HIF-1alpha/ARNT. EMBO J. 1998; 17 (17): 5085–5094. DOI: 10.1093/emboj/17.17.5085. PMID: 9724644.</mixed-citation><mixed-citation xml:lang="en">Zelzer E., Levy Y., Kahana C., Shilo B. Z., Rubinstein M., Cohen B. Insulin induces transcription of target genes through the hypoxiainducible factor HIF-1alpha/ARNT. EMBO J. 1998; 17 (17): 5085–5094. DOI: 10.1093/emboj/17.17.5085. PMID: 9724644.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Pilkis S. J., Granner D. K. Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. Annu Rev Physiol. 1992; 54: 885–909. DOI: 10.1146/annurev.ph.54.030192.004321. PMID: 1562196.</mixed-citation><mixed-citation xml:lang="en">Pilkis S. J., Granner D. K. Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. Annu Rev Physiol. 1992; 54: 885–909. DOI: 10.1146/annurev.ph.54.030192.004321. PMID: 1562196.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Taha C., Mitsumoto Y., Liu Z., Skolnik E. Y., Klip A. The insulin-dependent biosynthesis of GLUT1 and GLUT3 glucose transporters in L6 muscle cells is mediated by distinct pathways. Roles of p21ras and pp7o S6 kinase. J Biol Chem. 1995; 270 (42): 24678–24681. DOI: 10.1074/jbc.270.42.24678. PMID: 7559581.</mixed-citation><mixed-citation xml:lang="en">Taha C., Mitsumoto Y., Liu Z., Skolnik E. Y., Klip A. The insulin-dependent biosynthesis of GLUT1 and GLUT3 glucose transporters in L6 muscle cells is mediated by distinct pathways. Roles of p21ras and pp7o S6 kinase. J Biol Chem. 1995; 270 (42): 24678–24681. DOI: 10.1074/jbc.270.42.24678. PMID: 7559581.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Masuda S., Chikuma M., Sasaki R. Insulin-like growth factors and insulin stimulate erythropoietin production in primary cultured astrocytes. Brain Res. 1997; 746 (1–2): 63–70. DOI: 10.1016/S0006-8993(96)01186-9. PMID: 9037485.</mixed-citation><mixed-citation xml:lang="en">Masuda S., Chikuma M., Sasaki R. Insulin-like growth factors and insulin stimulate erythropoietin production in primary cultured astrocytes. Brain Res. 1997; 746 (1–2): 63–70. DOI: 10.1016/S0006-8993(96)01186-9. PMID: 9037485.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Miele C., Rochford J. J., Filippa N., Giorgetti-Peradi S., Van Obberghen E. Insulin and insulin-like growth factor-I induce vascular endothelial growth factor mRNA expression via different signaling pathways. J Biol Chem. 2000; 275 (28): 21695–21702. DOI: 10.1074/jbc.M000805200. PMID: 10777488.</mixed-citation><mixed-citation xml:lang="en">Miele C., Rochford J. J., Filippa N., Giorgetti-Peradi S., Van Obberghen E. Insulin and insulin-like growth factor-I induce vascular endothelial growth factor mRNA expression via different signaling pathways. J Biol Chem. 2000; 275 (28): 21695–21702. DOI: 10.1074/jbc.M000805200. PMID: 10777488.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Treins C., Giorgetti-Peraldi S., Murdaca J., Semenza G. L., Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem. 2002; 277 (31): 27975-27981. DOI: 10.1074/jbc.M204152200. PMID: 12032158.</mixed-citation><mixed-citation xml:lang="en">Treins C., Giorgetti-Peraldi S., Murdaca J., Semenza G. L., Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem. 2002; 277 (31): 27975-27981. DOI: 10.1074/jbc.M204152200. PMID: 12032158.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Stiehl D. P., Jelkmann W., Wenger R. H., Hellwig-Bürgel T. Normoxic induction of the hypoxia-inducible factor 1alpha by insulin and interleukin-1beta involves the phosphatidylinositol 3-kinase pathway. FEBS Lett. 2002; 512 (1-3): 157–162. DOI: 10.1016/S0014-5793(02)02247-0. PMID: 11852072.</mixed-citation><mixed-citation xml:lang="en">Stiehl D. P., Jelkmann W., Wenger R. H., Hellwig-Bürgel T. Normoxic induction of the hypoxia-inducible factor 1alpha by insulin and interleukin-1beta involves the phosphatidylinositol 3-kinase pathway. FEBS Lett. 2002; 512 (1-3): 157–162. DOI: 10.1016/S0014-5793(02)02247-0. PMID: 11852072.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Russo V., Candeloro P., Malara N., Perozziello G., Iannone M., Scicchitano M., Mollace R., et al. Key role of cytochrome C for apoptosis detection using Raman microimaging in an animal model of brain ischemia with insulin treatment. Appl Spectrosc. 2019; 73 (10): 1208–1217. DOI: 10.1177/0003702819858671. PMID: 31219322.</mixed-citation><mixed-citation xml:lang="en">Russo V., Candeloro P., Malara N., Perozziello G., Iannone M., Scicchitano M., Mollace R., et al. Key role of cytochrome C for apoptosis detection using Raman microimaging in an animal model of brain ischemia with insulin treatment. Appl Spectrosc. 2019; 73 (10): 1208–1217. DOI: 10.1177/0003702819858671. PMID: 31219322.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Storozheva Z. I., Proshin A. T., Sherstnev V. V., Storozhevykh T., Senilova Y. E., Persyantseva N. A., Pinelis V. G., et al. Dicholine salt of succinic acid, a neuronal insulin sensitizer, ameliorates cognitive deficits in rodent models of normal aging, chronic cerebral hypoperfusion, and beta-amyloid peptide-(25-35)-induced amnesia. BMC Pharmacol. 2008; 8: 1. DOI: 10.1186/1471-2210-8-1. PMID: 18215309.</mixed-citation><mixed-citation xml:lang="en">Storozheva Z. I., Proshin A. T., Sherstnev V. V., Storozhevykh T., Senilova Y. E., Persyantseva N. A., Pinelis V. G., et al. Dicholine salt of succinic acid, a neuronal insulin sensitizer, ameliorates cognitive deficits in rodent models of normal aging, chronic cerebral hypoperfusion, and beta-amyloid peptide-(25-35)-induced amnesia. BMC Pharmacol. 2008; 8: 1. DOI: 10.1186/1471-2210-8-1. PMID: 18215309.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Pomytkin I. A., Semenova N. A. Study of the effect of preconditioning with succinic acid salt of choline (1:2) on the disturbances of energy metabolism in the brain during ischemia by 31P NMR in vivo. Dokl Biochem Biophys. 2005; 403: 289–292. DOI: 10.1007/s10628-005-0094-7. PMID: 16229144.</mixed-citation><mixed-citation xml:lang="en">Pomytkin I. A., Semenova N. A. Study of the effect of preconditioning with succinic acid salt of choline (1:2) on the disturbances of energy metabolism in the brain during ischemia by 31P NMR in vivo. Dokl Biochem Biophys. 2005; 403: 289–292. DOI: 10.1007/s10628-005-0094-7. PMID: 16229144.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Pomytkin I. A., Storozheva Z. I., Semenova N. A., Proshin A. T., Sherstnev V. V., Varfolomeev S. D. Neuroprotective effect of choline succinate in rats with experimental chronic cerebral ischemia evaluated by cognitive ability tests. Biol Bull. 2007; 34 (2): 144–147.</mixed-citation><mixed-citation xml:lang="en">Pomytkin I. A., Storozheva Z. I., Semenova N. A., Proshin A. T., Sherstnev V. V., Varfolomeev S. D. Neuroprotective effect of choline succinate in rats with experimental chronic cerebral ischemia evaluated by cognitive ability tests. Biol Bull. 2007; 34 (2): 144–147.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Esposito E., Desai R., Ji X., Lo E. H. Pharmacologic pre- and postconditioning for stroke: Basic mechanisms and translational opportunity. Brain Circ. 2015; 1: 104–113. DOI: 10.4103/2394-8108.166380.</mixed-citation><mixed-citation xml:lang="en">Esposito E., Desai R., Ji X., Lo E. H. Pharmacologic pre- and postconditioning for stroke: Basic mechanisms and translational opportunity. Brain Circ. 2015; 1: 104–113. DOI: 10.4103/2394-8108.166380.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Помыткин И. А., Писарев В. В., Меркулов М. Е., Кузнецова Е. Б., Салина Е. А., Малыгин А. Ю., Каркищенко Н. Н. Результаты клинического исследования II фазы лекарственного репарата Дирекорд: рандомизированное, двойное слепое, плацебоконтролируемое, с параллельными группами, проспективное исследование по подбору оптимальной дозировки и изучению эффективности, безопасности и переносимости у пациентов с ишемическим инсультом в раннем восстановительном периоде. Биомедицина. 2023; 19 (3): 87–96. DOI: 10.33647/2074-5982-19-3-87-96.</mixed-citation><mixed-citation xml:lang="en">Pomytkin I. A., Pisarev V. V., Merkulov M. E., Kuznetsova E. B., Salina E. A., Malygin A.Yu., Karkishchenko N. N. Phase II of clinical trial of Direkord: randomized, double-blind, placebo-controlled, parallel group, and prospective study to select optimal dosage and to study the efficacy, safety, and tolerability in ischemic stroke patients in the early recovery period. Biomedicine = Biomeditsina. 2023; 19 (3): 87–96. (in Russ.). DOI: 10.33647/2074-5982-19-3-87-96.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Помыткин И. А., Писарев В. В., Меркулов М. Е., Лукиных Л. В., Моржухина М. В., Каркищенко Н. Н. Результаты клинического исследования III фазы: многоцентровое рандомизированное двойное слепое плацебо-контролируемое в параллельных группах исследование эффективности и безопасности лекарственного препарата Дирекорд у пациентов с ишемическим инсультом в раннем восстановительном периоде. Биомедицина. 2023; 19 (4): 81–93. DOI: 10.33647/2074-5982-19-4-81-93.</mixed-citation><mixed-citation xml:lang="en">Pomytkin I. A., Pisarev V. V., Merkulov M. E., Lukinykh L. V., Morzhukhina M. V., Karkischenko N. N. Results of phase III clinical trial: a multicenter randomized, double-blind, placebo-controlled, parallel group study of the efficacy and safety of Direkord in ischemic stroke patients in early recovery period. Biomedicine = Biomeditsina. 2023; 19 (3): 87–96. (in Russ.). DOI: 10.33647/2074-5982-19-4-81-93.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Berthet C., Castillo X., Magistretti P. J., Hirt L. New evidence of neuroprotection by lactate after transient focal cerebral ischaemia: extended benefit after intracerebroventricular injection and efficacy of intravenous administration. Cerebrovasc Dis. 2012; 34 (5–6): 329–335. DOI: 10.1159/000343657. PMID: 23154656.</mixed-citation><mixed-citation xml:lang="en">Berthet C., Castillo X., Magistretti P. J., Hirt L. New evidence of neuroprotection by lactate after transient focal cerebral ischaemia: extended benefit after intracerebroventricular injection and efficacy of intravenous administration. Cerebrovasc Dis. 2012; 34 (5–6): 329–335. DOI: 10.1159/000343657. PMID: 23154656.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Jourdain P., Rothenfusser K., Ben-Adiba C., Allaman I., Marquet P., Magistretti P. J. Dual action of L-Lactate on the activity of NR2B-containing NMDA receptors: from potentiation to neuroprotection. Sci Rep. 2018; 8 (1): 13472. DOI: 10.1038/s41598-018-31534-y. PMID: 30194439.</mixed-citation><mixed-citation xml:lang="en">Jourdain P., Rothenfusser K., Ben-Adiba C., Allaman I., Marquet P., Magistretti P. J. Dual action of L-Lactate on the activity of NR2B-containing NMDA receptors: from potentiation to neuroprotection. Sci Rep. 2018; 8 (1): 13472. DOI: 10.1038/s41598-018-31534-y. PMID: 30194439.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Jourdain P., Allaman I., Rothenfusser K., Fiumelli H., Marquet P., Magistretti P. J. L-Lactate protects neurons against excitotoxicity: implication of an ATP-mediated signaling cascade. Sci Rep. 2016; 6: 21250. DOI: 10.1038/srep21250. PMID: 26893204.</mixed-citation><mixed-citation xml:lang="en">Jourdain P., Allaman I., Rothenfusser K., Fiumelli H., Marquet P., Magistretti P. J. L-Lactate protects neurons against excitotoxicity: implication of an ATP-mediated signaling cascade. Sci Rep. 2016; 6: 21250. DOI: 10.1038/srep21250. PMID: 26893204.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Cerina M., Levers M., Keller J. M., Frega M. Neuroprotective role of lactate in a human in vitro model of the ischemic penumbra. Sci Rep. 2024; 14: 7973. DOI: 10.1038/s41598-024-58669-5. PMID: 38575687.</mixed-citation><mixed-citation xml:lang="en">Cerina M., Levers M., Keller J. M., Frega M. Neuroprotective role of lactate in a human in vitro model of the ischemic penumbra. Sci Rep. 2024; 14: 7973. DOI: 10.1038/s41598-024-58669-5. PMID: 38575687.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Sanderson T. H., Reynolds C. A., Kumar R., Przyklenk K., M. Molecular mechanisms of ischemia-reperfusion injury in brain: pivotal role of the mitochondrial membrane potential in reactive oxygen species generation. Mol Neurobiol. 2013; 47 (1): 9–23. DOI: 10.1007/s12035-012-8344-z. PMID: 23011809.</mixed-citation><mixed-citation xml:lang="en">Sanderson T. H., Reynolds C. A., Kumar R., Przyklenk K., M. Molecular mechanisms of ischemia-reperfusion injury in brain: pivotal role of the mitochondrial membrane potential in reactive oxygen species generation. Mol Neurobiol. 2013; 47 (1): 9–23. DOI: 10.1007/s12035-012-8344-z. PMID: 23011809.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
